CanSino Biologics Management

Management criteria checks 3/4

CanSino Biologics' CEO is Xuefeng Yu, appointed in Jan 2009, has a tenure of 15.25 years. directly owns 7.24% of the company’s shares, worth €72.15M. The average tenure of the management team and the board of directors is 6.2 years and 4.4 years respectively.

Key information

Xuefeng Yu

Chief executive officer

CN¥4.9m

Total compensation

CEO salary percentage	n/a
CEO tenure	15.3yrs
CEO ownership	7.2%
Management average tenure	6.2yrs
Board average tenure	4.4yrs

Recent management updates

Recent updates

CEO

Xuefeng Yu (58 yo)

15.3yrs

Tenure

CN¥4,940,000

Compensation

Dr. Xuefeng Yu, Ph D, is Co-Founder of CanSino Biologics Inc. since 2009. Dr. Yu serves as an Executive Director at CanSino Biologics Inc. since January 13, 2009 and has served as its Chief Executive Offic...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Xuefeng Yu	Co-Founder	15.3yrs	CN¥4.94m	7.24% CN¥ 72.2m
Tao Zhu	Co-Founder	15.3yrs	CN¥4.98m	7.24% CN¥ 72.2m
Dongxu Qiu	Co-Founder	15.3yrs	CN¥4.61m	6.93% CN¥ 69.1m
Shou-Bai Chao	COO, Deputy GM & Executive Director	5.9yrs	CN¥4.91m	no data
Jing Wang	Chief Commercial Officer	2.6yrs	CN¥3.97m	no data
Chunlin Xin	Senior Director of New Technology Department	6.4yrs	no data	no data
Yonghui Wu	Vice President of Marketing	no data	no data	no data
Jin Cui	Board Secretary	5.1yrs	no data	no data
Ming King Chiu	Joint Company Secretary	5.1yrs	no data	no data

6.2yrs

Average Tenure

49yo

Average Age

Experienced Management: CJH's management team is seasoned and experienced (6.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Xuefeng Yu	Co-Founder	15.3yrs	CN¥4.94m	7.24% CN¥ 72.2m
Tao Zhu	Co-Founder	15.3yrs	CN¥4.98m	7.24% CN¥ 72.2m
Dongxu Qiu	Co-Founder	15.3yrs	CN¥4.61m	6.93% CN¥ 69.1m
Shou-Bai Chao	COO, Deputy GM & Executive Director	5.8yrs	CN¥4.91m	no data
Jing Wang	Chief Commercial Officer	2.5yrs	CN¥3.97m	no data
George R. Siber	Co-Chair of Scientific Advisory Board	1.3yrs	no data	no data
Shuifa Gui	Independent Non-Executive Director	4.4yrs	CN¥300.00k	no data
David Briles	Member of Scientific Advisory Board	no data	no data	no data
Zhi Xiao	Chairman of Employee Representative Supervisor	less than a year	no data	no data
Jianzhong Liu	Independent Non-Executive Director	4.4yrs	CN¥300.00k	0.00040% CN¥ 4.0k
Liming Li	Co-Chair of Scientific Advisory Board	1.3yrs	no data	no data
Leung Cheung Yiu	Independent Non-Executive Director	no data	no data	no data

4.4yrs

Average Tenure

58yo

Average Age

Experienced Board: CJH's board of directors are considered experienced (4.4 years average tenure).

CanSino Biologics Management

Management criteria checks 3/4

Key information

Recent management updates

Less than half of directors are independent

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc., Annual General Meeting, Jun 30, 2023

Non-Executive Director recently sold €414k worth of stock

Less than half of directors are independent

Recent updates

Cansino Biologics Inc. Announces Positive Preliminary Results from Phase I Clinical Trials of the Protein-Based Pneumococcal Vaccine

Full year 2023 earnings released: CN¥6.01 loss per share (vs CN¥3.68 loss in FY 2022)

CanSino Biologics Inc. to Report Q1, 2024 Results on Apr 30, 2024

Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine

Full year 2023 earnings released: CN¥5.87 loss per share (vs CN¥3.68 loss in FY 2022)

Less than half of directors are independent

Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023

CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine

Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Enrollment for TDCP Adolescent and Adult

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case

Second quarter 2023 earnings released: CN¥2.82 loss per share (vs CN¥0.44 loss in 2Q 2022)

CanSino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc. Announces CS-2032 Zoster Vaccine Obtains Clinical Trial Approval from Canada

CanSino Biologics Inc. to Report First Half, 2023 Results on Aug 22, 2023

Cansino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc., Annual General Meeting, Jun 30, 2023

Full year 2022 earnings released: CN¥3.65 loss per share (vs CN¥7.74 profit in FY 2021)

CanSino Biologics Inc. Provides Earnings Guidance for the Period from January 1, 2022 to December 31, 2022

Non-Executive Director recently sold €414k worth of stock

Cansino Biologics Inc. Announces Covid-19 Mrna Vaccine Cs-2034 Achieved Positive Interim Data in A Clinical Trial Evaluating the Safety and Immunogenicity of the Heterologous Cs-2034 Booster

CanSino Biologics Inc. Announces Clinical Research Results of A Clinical Trial of Bivalent Recombinant Covid-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation in Adults Aged 18 Years and Above

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

Less than half of directors are independent

CanSino Biologics Inc.'s Recombinant Covid-19 Vaccine (Adenovirus Type 5Vector) for Inhalation Approved for Emergency Use in Morocco

Now 31% undervalued

Third quarter 2022 earnings released

Investor sentiment improved over the past week

CanSino Biologics Inc. to Report Q3, 2022 Results on Oct 28, 2022

CanSino Biologics Inc. Recombinant Covid-19 Vaccine for Inhalation Included for Emergency Use as A Booster Vaccine in PRC

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: CN¥0.44 loss per share (vs CN¥3.67 profit in 2Q 2021)

CanSino Biologics Inc. to Report Q2, 2022 Results on Aug 26, 2022

Investor sentiment deteriorated over the past week

Cansino Biologics Inc. Announces Dividend for the Financial Year Ended December 31, 2021 Payable on 19 August 2022

Less than half of directors are independent

CanSino Biologics Inc., Annual General Meeting, Jun 29, 2022

CanSino Biologics Inc., Annual General Meeting, Jun 29, 2022

CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing

First quarter 2022 earnings released: EPS: CN¥0.49 (vs CN¥0.06 loss in 1Q 2021)

Less than half of directors are independent

CanSino Biologics Inc. to Report Q1, 2022 Results on Apr 28, 2022

Cansino Biologics Inc. Proposes Dividend for the Financial Year Ended 31 December 2021

Less than half of directors are independent

CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

CanSino Biologics Inc. announces Convidecia Approve as Heterologous Booster in China

Investor sentiment deteriorated over the past week

CanSino Biologics Inc. (SEHK:6185) announces an Equity Buyback for CNY 300 million worth of its shares.

CanSinoBIO's Shows Encouraging Results for Inhaled COVID-19 Vaccine as Heterologous Booster

CanSino Biologics Inc. Announces Approval for its MCV4 Product Menhycia in China

CanSino Biologics Inc. Announces the National Medical Products Administration of China Grants New Drug Approval to Menhycia

CanSino Biologics Inc. Announces Convidecia™ Phase III Results Published in The Lancet

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Non-Executive Director Qiang Xu has left the company

Non-Executive Director recently sold €3.6m worth of stock

CanSino Biologics Inc. Announces New Drug Application Approval for Mcv2 Granted by the National Medical Products Administration of China

Supervisor Jieyu Zou has left the company

First quarter 2021 earnings released

Full year 2020 earnings released: CN¥1.72 loss per share (vs CN¥0.77 loss in FY 2019)

CanSino Biologics Inc. to Report Fiscal Year 2020 Results on Mar 29, 2021

Cansino Biologics Inc. Announces NMPA'S Acceptence of Application for Conditional Marketing Authorization of Recombinant Novel Coronavirus Vaccine